ELEKTA AB/ADR (EKTAY) Upgraded at Zacks Investment Research
According to Zacks, “Elekta AB is a human care company engaged in developing and selling clinical solutions for the treatment of cancer and neurological diseases. It develops tools and treatment planning systems for radiation therapy, radiosurgery and brachytherapy, as well as workflow enhancing software systems across the spectrum of cancer care. The Company’s offering is divided into five areas: Neuroscience, Oncology, Software, Brachytherapy and Services. Elekta AB is headquartered in Stockholm, Sweden. “
Separately, ValuEngine cut shares of ELEKTA AB/ADR from a buy rating to a hold rating in a report on Tuesday.
ELEKTA AB/ADR (OTCMKTS:EKTAY) last posted its quarterly earnings data on Friday, February 22nd. The company reported $0.06 earnings per share for the quarter. ELEKTA AB/ADR had a net margin of 9.35% and a return on equity of 16.86%. The company had revenue of $367.04 million during the quarter. As a group, research analysts anticipate that ELEKTA AB/ADR will post 0.35 earnings per share for the current fiscal year.
The business also recently declared a Semi-Annual dividend, which was paid on Friday, March 22nd. Shareholders of record on Monday, March 4th were issued a $0.052 dividend. The ex-dividend date of this dividend was Friday, March 1st. ELEKTA AB/ADR’s payout ratio is 28.57%.
ELEKTA AB/ADR Company Profile
Elekta AB (publ) provides equipment and software for cancer and brain disorders worldwide. The company offers radiotherapy systems under the Versa HD, Precise Treatment System, and Elekta Compact names; Elekta Infinity, an image-guided radiation therapy (IGRT) system; and Elekta Synergy, a digital accelerator for advanced IGRT.
See Also: Channel Trading
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for ELEKTA AB/ADR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ELEKTA AB/ADR and related companies with MarketBeat.com's FREE daily email newsletter.